Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Weekly News Recap #Phispers
1. 2-isopropyl-5-(2-phenylethenyl)benzene-1,3-diol
2. 3,5-dh4is
3. 5-(2-phenylethenyl)-2-isopropyl-1,3-benzenediol
4. Benvitimod
5. Gsk2894512
6. Tapinarof
7. Wbi-1001
1. Benvitimod
2. Tapinarof
3. 79338-84-4
4. Wbi-1001
5. Gsk2894512
6. Vtama
7. Wbi 1001
8. Tapinarof [usan]
9. 3,5-dihydroxy-4-isopropyl-trans-stilbene
10. (e)-2-(1-methylethyl)-5-(2-phenylethenyl)-1,3-benzenediol
11. 2-isopropyl-5-styrylbenzene-1,3-diol
12. Gsk-2894512
13. 5-[(e)-2-phenylethenyl]-2-propan-2-ylbenzene-1,3-diol
14. (e)-2-isopropyl-5-styrylbenzene-1,3-diol
15. 84hw7d0v04
16. Tapinarof (usan)
17. 1,3-benzenediol, 2-(1-methylethyl)-5-[(1e)-2-phenylethenyl]-
18. 115781-08-3
19. 1,3-benzenediol, 2-(1-methylethyl)-5-(2-phenylethenyl)-, (e)-
20. 3,5-dh4is
21. Unii-84hw7d0v04
22. 1,3-benzenediol, 2-(1-methylethyl)-5-((1e)-2-phenylethenyl)-
23. Benvitimod (tapinarof)
24. Tapinarof [inn]
25. Tapinarof [who-dd]
26. Schembl918343
27. Chembl259571
28. Gtpl9686
29. Dtxsid301045262
30. Bcp13569
31. Ex-a4877
32. Zinc5761533
33. (e)-4-isopropylstilbene-3,5-diol
34. Mfcd13193203
35. S9700
36. Akos025296109
37. Db06083
38. Wb-1001
39. Ac-36567
40. As-44364
41. Hy-109044
42. Cs-0031487
43. D11365
44. A914284
45. Q4634086
46. 2-(1-methylethyl)-5-[(e)-2-phenylethenyl]benzene-1,3-diol
47. 2-(1-methylethyl)-5-((1e)-2-phenylethenyl)-1,3-benzenediol
48. 5-((1e)-2-phenylethen-1-yl)-2-(propan-2-yl)benzene-1,3-diol
Molecular Weight | 254.32 g/mol |
---|---|
Molecular Formula | C17H18O2 |
XLogP3 | 4.6 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 3 |
Exact Mass | 254.130679813 g/mol |
Monoisotopic Mass | 254.130679813 g/mol |
Topological Polar Surface Area | 40.5 Ų |
Heavy Atom Count | 19 |
Formal Charge | 0 |
Complexity | 280 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in psoriasis and psoriatic disorders.
WBI-1001 selectively modulates the cytokine cascade deep under the skin, a process that rapidly decreases inflammations and skin plague. It targets the four major mechanisms involved in the disease.
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Vtama (tapinarof) cream is an aryl hydrocarbon receptor agonist steroid-free, topical cream, for the treatment of atopic dermatitis in adults & children 2 years of age & above.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2024
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves VTAMA® Cream for Adults and Kids Aged 2+ with Atopic Dermatitis
Details : Vtama (tapinarof) cream is an aryl hydrocarbon receptor agonist steroid-free, topical cream, for the treatment of atopic dermatitis in adults & children 2 years of age & above.
Product Name : Vtama
Product Type : Small molecule
Upfront Cash : Not Applicable
December 16, 2024
Details:
Vtama (tapinarof) cream is an aryl hydrocarbon receptor agonist steroid-free, topical cream, for the treatment of atopic dermatitis in adults & children 2 years of age & above.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2024
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
VTAMA® Update on FDA Review for Atopic Dermatitis Treatment
Details : Vtama (tapinarof) cream is an aryl hydrocarbon receptor agonist steroid-free, topical cream, for the treatment of atopic dermatitis in adults & children 2 years of age & above.
Product Name : Vtama
Product Type : Small molecule
Upfront Cash : Not Applicable
November 05, 2024
Details:
Through the acquisition, Organon will leverage the Dermavant pipeline, which includes Vtama (tapinarof) cream. It is indicated for the treatment of f plaque psoriasis in adults.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Organon
Deal Size: $1,200.0 million Upfront Cash: $175.0 million
Deal Type: Acquisition October 28, 2024
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Organon
Deal Size : $1,200.0 million
Deal Type : Acquisition
Organon Acquires Dermavant's VTAMA® Cream for Dermatology
Details : Through the acquisition, Organon will leverage the Dermavant pipeline, which includes Vtama (tapinarof) cream. It is indicated for the treatment of f plaque psoriasis in adults.
Product Name : Vtama
Product Type : Small molecule
Upfront Cash : $175.0 million
October 28, 2024
Details:
Through the acquisition, Organon will leverage the Dermavant pipeline, which includes Vtama (tapinarof) cream. It is indicated for the treatment of f plaque psoriasis in adults.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Organon
Deal Size: $1,200.0 million Upfront Cash: $175.0 million
Deal Type: Acquisition September 18, 2024
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Organon
Deal Size : $1,200.0 million
Deal Type : Acquisition
Organon Pays up to $1.2B to Acquire Dermavant and its Steroid-Free Skin Cream Vtama
Details : Through the acquisition, Organon will leverage the Dermavant pipeline, which includes Vtama (tapinarof) cream. It is indicated for the treatment of f plaque psoriasis in adults.
Product Name : Vtama
Product Type : Small molecule
Upfront Cash : $175.0 million
September 18, 2024
Details:
Vtama (tapinarof) cream is an aryl hydrocarbon receptor agonist steroid-free, topical cream, for the treatment of psoriasis in adults and atopic dermatitis in adults & children 2 years of age & above.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2024
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Dermavant Announces Approval of Tapinarof in both Psoriasis and Atopic Dermatitis in Japan
Details : Vtama (tapinarof) cream is an aryl hydrocarbon receptor agonist steroid-free, topical cream, for the treatment of psoriasis in adults and atopic dermatitis in adults & children 2 years of age & above.
Product Name : Vtama
Product Type : Small molecule
Upfront Cash : Not Applicable
June 25, 2024
Details:
Vtama (tapinarof) cream is a novel aryl hydrocarbon receptor agonist for once-daily topical treatment of atopic dermatitis in patients 2 years and older.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2024
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Dermavant Announces FDA Acceptance Of sNDA for VTAMA® Cream
Details : Vtama (tapinarof) cream is a novel aryl hydrocarbon receptor agonist for once-daily topical treatment of atopic dermatitis in patients 2 years and older.
Product Name : Vtama
Product Type : Small molecule
Upfront Cash : Not Applicable
April 29, 2024
Details:
Vtama (tapinarof) cream is a novel aryl hydrocarbon receptor agonist, developed as a once-daily, steroid-free topical cream for atopic dermatitis in adults and children 2 years and older.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Dermavant Submits sNDA for VTAMA® Cream, 1% for Atopic Dermatitis
Details : Vtama (tapinarof) cream is a novel aryl hydrocarbon receptor agonist, developed as a once-daily, steroid-free topical cream for atopic dermatitis in adults and children 2 years and older.
Product Name : Vtama
Product Type : Small molecule
Upfront Cash : Not Applicable
February 14, 2024
Details:
Vtama (tapinarof) cream is a novel aryl hydrocarbon receptor agonist, in phase 3 trials as a once-daily, steroid-free topical cream for Atopic Dermatitis.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2024
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Dermavant Reports Positive Data from ADORING Program with VTAMA® Cream
Details : Vtama (tapinarof) cream is a novel aryl hydrocarbon receptor agonist, in phase 3 trials as a once-daily, steroid-free topical cream for Atopic Dermatitis.
Product Name : Vtama
Product Type : Small molecule
Upfront Cash : Not Applicable
January 11, 2024
Details:
Vtama (tapinarof) is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant and steroid-free, topical cream, for the treatment of plaque psoriasis in the head and neck region.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: Phase IVProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2023
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Dermavant Announces Positive Results from Phase 4 Open-Label Trial of VTAMA® (tapinarof) Cream, 1...
Details : Vtama (tapinarof) is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant and steroid-free, topical cream, for the treatment of plaque psoriasis in the head and neck region.
Product Name : Vtama
Product Type : Small molecule
Upfront Cash : Not Applicable
December 06, 2023
Details:
Vtama (tapinarof Cream 1%) is the first-in-class, steroid-free, once-daily topical treatment for moderate to severe atopic dermatitis in adults and children as young as two years old.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Vtama (tapinarof Cream 1%) is the first-in-class, steroid-free, once-daily topical treatment for moderate to severe atopic dermatitis in adults and children as young as two years old.
Product Name : Vtama
Product Type : Small molecule
Upfront Cash : Not Applicable
May 16, 2023
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
90
PharmaCompass offers a list of Tapinarof API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Tapinarof manufacturer or Tapinarof supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Tapinarof manufacturer or Tapinarof supplier.
PharmaCompass also assists you with knowing the Tapinarof API Price utilized in the formulation of products. Tapinarof API Price is not always fixed or binding as the Tapinarof Price is obtained through a variety of data sources. The Tapinarof Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Tapinarof manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tapinarof, including repackagers and relabelers. The FDA regulates Tapinarof manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tapinarof API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Tapinarof manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Tapinarof supplier is an individual or a company that provides Tapinarof active pharmaceutical ingredient (API) or Tapinarof finished formulations upon request. The Tapinarof suppliers may include Tapinarof API manufacturers, exporters, distributors and traders.
click here to find a list of Tapinarof suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Tapinarof DMF (Drug Master File) is a document detailing the whole manufacturing process of Tapinarof active pharmaceutical ingredient (API) in detail. Different forms of Tapinarof DMFs exist exist since differing nations have different regulations, such as Tapinarof USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Tapinarof DMF submitted to regulatory agencies in the US is known as a USDMF. Tapinarof USDMF includes data on Tapinarof's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Tapinarof USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Tapinarof suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tapinarof as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Tapinarof API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Tapinarof as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Tapinarof and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tapinarof NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Tapinarof suppliers with NDC on PharmaCompass.
Tapinarof Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tapinarof GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tapinarof GMP manufacturer or Tapinarof GMP API supplier for your needs.
A Tapinarof CoA (Certificate of Analysis) is a formal document that attests to Tapinarof's compliance with Tapinarof specifications and serves as a tool for batch-level quality control.
Tapinarof CoA mostly includes findings from lab analyses of a specific batch. For each Tapinarof CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tapinarof may be tested according to a variety of international standards, such as European Pharmacopoeia (Tapinarof EP), Tapinarof JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tapinarof USP).